5 analysts have expressed a variety of opinions on Arcturus Therapeutics ARCT over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes their ...

5 analysts have expressed a variety of opinions on Arcturus Therapeutics (NASDAQ:ARCT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below summarizes ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

In a report released yesterday, Myles Minter from William Blair maintained a Buy rating on Argenx Se. The company’s shares closed today at $591.99. Take advantage of TipRanks Premium at 50% off!

In a report released yesterday, Pete Stavropoulos from Cantor Fitzgerald maintained a Buy rating on Axsome Therapeutics, with a price target of $153.00. The company’s shares closed yesterday at ...

Arcturus Therapeutics Holdings Inc. research and ratings by Barron's. View ARCT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Review which funds and institutions currently hold Arcturus Therapeutics Holdings Inc (ARCT:XNAS) stock for ownership information.

In this episode presented by Eclipsebio, BioSpace's head of insights Lori Ellis continues the discussion on mRNA and srRNA with Andy Geall of Replicate Bioscience and Alliance for mRNA Medicines and ...